An internal Food and Drug Administration drug-safety oversight board narrowly voted to keep GlaxoSmithKline PLC's diabetes drug Avandia on the market, according to Senate Finance Committee investigators.
Sen. Charles Grassley (R., Iowa), the top Republican on the panel, who has been investigating the FDA's handling of drug-safety issues, said the drug-safety oversight board voted 8-7 earlier this month to keep Avandia on the U.S. market.
More at the WSJ
No comments:
Post a Comment